Harrow CFO Boll Adds Principal Accounting Officer Role After Pollard Exit – Minichart

Harrow (HROW) completed its acquisition of Tyrvaya, a dry eye treatment, from Viatris. Harrow paid $30M upfront, with up to $70M in milestones. Tyrvaya is FDA-approved and complements Harrow's existing dry eye therapy, Vevye. Harrow expects Tyrvaya to generate over $30M in 2027 revenue.

HARROW, INC. (HROW) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Harrow Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise NASHVILLE, Tenn., October 5, 2026 — Harrow (Nasdaq: HROW), a leading provi

Harrow (HROW) completed its $30M acquisition of TYRVAYA nasal spray from Viatris, with up to $70M in milestone payments. TYRVAYA, approved for dry eye disease, complements Harrow's VEVYE product. Harrow expects $30M+ revenue from TYRVAYA in 2027, with 40 Viatris employees joining its team.

Harrow (HROW) announced the departure of its Chief Accounting Officer, with the CFO taking over the role. The company's shares closed at $38.54, with mixed short-term momentum. Analysts suggest Harrow may be undervalued by 44%, citing strong growth potential in its ophthalmic drugs.

Harrow (HROW) announced positive clinical study results for its IHEEZO ophthalmic gel, showing reduced patient discomfort during intravitreal injections. The study is relevant for Harrow's focus on specialty eye care and may impact its revenue mix. Investors will watch for real-world adoption in retina practices.

Harrow Inc. (NASDAQ:HROW) reported positive results from a clinical study of its ocular anesthetic IHEEZO, showing significant pain reduction compared to a control. Analysts noted the findings support long-term growth and maintained an Outperform rating. HROW shares were down 1.33% at $41.50 on Friday.